产品简要
公司名称 :
HUABIO
产品类型 :
抗体
产品名称 :
血管假性血友病因子重组兔单克隆抗体[JJ09-34](ET1701-87)
目录 :
ET1701-87
规格 :
单克隆
价格 :
JJ09-34
克隆性 :
单克隆
宿主 :
domestic rabbit
共轭标签 :
未共轭
克隆名称 :
JJ09-34
反应物种 :
人类
应用 :
免疫印迹, 免疫组化-石蜡切片
更多信息或购买 :
产品信息
Catalog# :
ET1701-87
产品名称 :
血管假性血友病因子重组兔单克隆抗体[JJ09-34](ET1701-87)
类别 :
Recombinant Rabbit monoclonal primary
共轭 :
未共轭
克隆性 :
单克隆
克隆编号 :
JJ09-34
宿主 :
兔
应用 :
免疫印迹, 免疫组化-P
应用w/稀释 :
WB: 1:1, 000-1:5, 000;免疫组化-P:1:50-1:200
反应物种 :
人类
免疫原 :
重组蛋白
抗体亚型 :
IgG
靶蛋白 :
血管假性血友病因子
靶标.UniProt数据库 :
P04275
靶标.同义词 :
Coagulation factor VIII antibody; Coagulation factor VIII VWF antibody; F8VWF antibody; Factor VIII related antigen antibody; von Willebrand antigen 2 antibody; von Willebrand antigen II antibody; Von Willebrand disease antibody; VWD antibody; vWF antibody; VWF_HUMAN antibody
Target function/background :
Von Willebrand disease is a congenital bleeding disorder caused by defects in the von Willebrand factor protein (VWF). VWF is a multimeric glycoprotein that is found in endothelial cells, plasma and platelets, and it is involved in the coagulation of blood at injury sites. VWF acts as a carrier protein for Factor VIII, a cofactor required for coagulation, and it promotes platelet adhesion and aggregation. Several factors are known to stimulate the binding of VWF to platelets, including glycoprotein 1b, ristocetin, botrocetin, collagen, sulphatides and heparin. Of the several domains contained within VWF, the A1, A2 and A3 domains have been shown to mediate this activation. VWF is thought to undergo a variety of posttranslational modifications that influence the affinity and availability for Factor VII, including cleavage of the propeptide and formation of N-terminal intersubunit disulfide bonds.
产品形式 :
液体
纯化 :
蛋白质A亲和纯化
浓度 :
1微克/微升
储存缓冲液 :
1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
储存空调 :
Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles.
分子量 :
309 kDa
供应商 :
HUABIO
Volume :
100ul
价格 :
355
launch date :
2020&prior
更多信息或购买 :
公司信息
HUABIO
Founded in 2007, HUABIO is dedicated to developing high-quality antibodies that advance innovation. We are passionate about the accuracy, efficiency, and consistency of our products. That is why we have invested in new production platforms, like recombinant rabbit monoclonals, alpaca nanobodies, and adopted aggressive QA standards to deliver cutting-edge antibodies with uncompromised quality.
We hope to see you at your next discovery!
We hope to see you at your next discovery!